<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01269580</url>
  </required_header>
  <id_info>
    <org_study_id>20/2008_Cardiovascolare</org_study_id>
    <nct_id>NCT01269580</nct_id>
  </id_info>
  <brief_title>Diabetic Foot and Vascular Progenitor Cells</brief_title>
  <official_title>The Diabetic Foot: Relevance of Vascular Progenitor Cells as a Prognostic Marker of Cardiovascular Mortality, Restenosis, and Atherosclerotic Disease Progression in Treated Limb.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Multimedica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Multimedica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type of Study: Pilot Study monocenter Study Duration: 18 months Subject Participation&#xD;
      Duration: The patients are enrolled for the time of the blood withdrawl.&#xD;
&#xD;
      Follow up visit will be after 12 months from the enrollement.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      The project will have two major objectives:&#xD;
&#xD;
      A)To validate the prognostic value of vascular progenitor cells, identified by flow&#xD;
      cytometric analysis of antigenic phenotype, in a cohort of 109 patients with type-2 diabetes&#xD;
      complicated by ischemic foot ulcers. Events are: cardiovascular mortality, major amputation,&#xD;
      post-angioplasty restenosis , and development of new atherosclerotic plaques in treated limb&#xD;
      B)To determine the mechanisms responsible for vascular progenitor cell dysfunction in the&#xD;
      perspective of new therapies for the cure of the diabetic foot.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This collaborative project aims to produce significant outputs for the identification of&#xD;
      patients requiring intensification of therapy. Furthermore, the project will fill the gap in&#xD;
      current knowledge on the post-genomic alterations that render diabetic vascular progenitor&#xD;
      cells dysfunctional. In perspective, this might help us to design new therapies for the cure&#xD;
      of the diabetic foot, including but not limited to stem cell therapy.&#xD;
&#xD;
      Primary Objectives:&#xD;
&#xD;
      To validate the prognostic value of vascular progenitor cells, identified by flow cytometric&#xD;
      analysis of antigenic phenotype, in a cohort of 109 patients with type-2 diabetes complicated&#xD;
      by ischemic foot ulcers.&#xD;
&#xD;
      Events are:&#xD;
&#xD;
      Cardiovascular mortality Major amputation Post-angioplasty restenosis Development of new&#xD;
      atherosclerotic plaques in treated limb (follow up: 12 months).&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To determine the mechanisms responsible for vascular progenitor cell dysfunction in the&#xD;
      perspective of new therapies for the cure of the diabetic foot.&#xD;
&#xD;
      All the Units will contribute to the primary objective (to validate the prognostic value of&#xD;
      vascular progenitor cells, identified by flow cytometric analysis of antigenic phenotype, in&#xD;
      a cohort of 100 patients with type-2 diabetes complicated by ischemic foot ulcers).&#xD;
      Furthermore, each Unit will focus on specific mechanistic targets, according to pilot data&#xD;
      collected in previous and ongoing projects.&#xD;
&#xD;
      Dr Faglia, Head of the Diabetology Unit, Diabetic Foot Centre (IRCCS Multimedica-MM), will&#xD;
      conduct the selection and enrollement of the patients, and collect all the clinical data for&#xD;
      the study at the 12 month follow up visit.&#xD;
&#xD;
      The Unit leaded by Prof. Madeddu (IRCCS Multimedica), will perform the antigenic&#xD;
      characterization of the vascular progenitor cells by flow cytometry, and conduct the&#xD;
      migration assays.&#xD;
&#xD;
      The Unit leaded by Prof. Madeddu (IRCCS Multimedica)and the Unit leaded by Dr. Gaetano and&#xD;
      Martelli (IDI, Rome) will be engaged with determining whether vascular progenitor cells&#xD;
      dysfunction is mediated by specific epigenetic modifications. Epigenetics refers to the&#xD;
      covalent modifications found in chromatin, on both the DNA and the accompanying histone&#xD;
      proteins.&#xD;
&#xD;
      The Unit of Dr. Germani (IDI, Rome) will be focused on identification of growth factors,&#xD;
      chemokines and cytokines in the serum of diabetic patients that could be involved in the&#xD;
      deregulation of progenitor functions.&#xD;
&#xD;
      Since normal criteria are not already available, to conduct the analyses performed by the UO&#xD;
      IDI, we need to enrol a group of 30 not-diabetic subjects age- and sex-matched to identify&#xD;
      key changes to analyze in the entire group of patients.&#xD;
&#xD;
      Thirty patients coming to MM, UO Vascular Surgery, Dr Losa, for varicose vein treatment or&#xD;
      carotid stenosis will be enrolled and subjected to blood withdrawal as described for the&#xD;
      diabetic patients group.&#xD;
&#xD;
      Subject Inclusion Criteria:&#xD;
&#xD;
      Adult diabetic patients type 1 or 2, both men and women, with chronic critical ischemia as&#xD;
      defined by TASC 2007 criteria (pain at rest, and/or ulcer or gangrene due to artheropaty:&#xD;
      transcutaneous oximetry &lt; 30 mmHg or pressure on the ankle &lt; 70 mmHg).&#xD;
&#xD;
      Subject Exclusion Criteria:&#xD;
&#xD;
        -  Cancer with adverse prognosis in months, or chemotherapic treatment&#xD;
&#xD;
        -  Ongoing or planned pregnancy&#xD;
&#xD;
        -  Lack of consent to participate to the study&#xD;
&#xD;
      Patients enrolment&#xD;
&#xD;
      At this time all patients will undergo all the following exams:&#xD;
&#xD;
        -  General comprehensive visit (including: Chest RX, Rest ECG, and glycaemia plus&#xD;
           glycosilated haemoglobin measurement)&#xD;
&#xD;
        -  Ankle arterial pressure (Doppler cw measurement)&#xD;
&#xD;
        -  Angiographyc study and angioplasty,if feasible, in the same time&#xD;
&#xD;
      IMPORTANT NOTE: At the enrolment visit and at follow up visit after 12 months will be&#xD;
      performed:&#xD;
&#xD;
        -  Ecodoppler&#xD;
&#xD;
        -  Transcutaneous oximetry&#xD;
&#xD;
        -  Completion of antigenic profiling&#xD;
&#xD;
        -  Assessment of migratory capacity&#xD;
&#xD;
        -  Characterization of major epigenetic signatures&#xD;
&#xD;
        -  Paracrine profiling&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>post revascularization cardiovascualr mortality</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>post revascularization amputation</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>post revascularization restenosis</measure>
    <time_frame>18 months</time_frame>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">122</enrollment>
  <condition>Diabetes</condition>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>Diabetic</arm_group_label>
    <description>Adult diabetic patients type 1 or 2, with chronic critical ischemia as defined by TASC 2007 criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Not diabetic</arm_group_label>
    <description>Adult not diabetic with chronic critical ischemia</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Diabetic patients with peripheral ischemia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult diabetic patients type 1 or 2&#xD;
&#xD;
          -  Chronic critical ischemia as defined by TASC 2007 criteria (pain at rest, and/or ulcer&#xD;
             or gangrene due to artheropaty: transcutaneous oximetry &lt; 30 mmHg or pressure on the&#xD;
             ankle &lt; 70 mmHg)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cancer with adverse prognosis in months, or chemotherapic treatment&#xD;
&#xD;
          -  Ongoing or planned pregnancy&#xD;
&#xD;
          -  Lack of consent to participate to the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ezio Faglia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Multimedica</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetic Foot Center IRCCS MultiMedica</name>
      <address>
        <city>Sesto San Giovanni</city>
        <state>Milan</state>
        <zip>20099</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>January 3, 2011</study_first_submitted>
  <study_first_submitted_qc>January 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2011</study_first_posted>
  <last_update_submitted>August 7, 2013</last_update_submitted>
  <last_update_submitted_qc>August 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

